Drug maker Glenmark Pharmaceuticals today said its subsidiary Glenmark Generics has filed the draft prospectus with marker regulator Securities and Exchange Board of India (SebiI) for an initial public offer (IPO).
"Glenmark Generics, has, on September 30, filed the draft red herring prospectus (DRHP) with Sebi for an Initial Public Offer," Glenmark Pharmaceuticals said in a filing to the Bombay Stock Exchange (BSE).
Drug maker did not disclose any further details about the public issue.
